Clicky

Acorda Therapeutics, Inc.(ACOR)

Description: Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.


Keywords: Biopharmaceutical Antibodies Autoimmune Disease Clinical Trial Potassium Multiple Sclerosis Heart Failure Stroke Chloride DSL Central Nervous System Disorders Spas Nervous System Disorders Seizure Spinal Cord Nasal Spray Spinal Cord Injury Cerebral Palsy Treatment Of Heart Failure Spasticity Acorda Therapeutics Treatment Of Ms Zanaflex

Home Page: www.acorda.com

ACOR Technical Analysis

420 Saw Mill River Road
Ardsley, NY 10502
United States
Phone: 914 347 4300


Officers

Name Title
Dr. Ron Cohen M.D. Founder, CEO, Pres & Director
Dr. Burkhard Blank M.D. Interim Head of Drug Safety
Mr. Michael A. Gesser M.B.A. Chief Financial Officer
Mr. Robert Morales Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller
Ms. Felicia Vonella VP of Investor Relations
Mr. Neil S. Belloff Esq. Gen. Counsel & Corp. Sec.
Ms. Tierney Saccavino Exec. VP of Corp. Communications
Ms. Denise J. Duca Exec. VP of HR
Mr. Andrew Mayer J.D. Sr. VP
Mr. Kerry M. Clem Chief Commercial Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.1677
Price-to-Sales TTM: 0.1079
IPO Date: 2006-02-10
Fiscal Year End: December
Full Time Employees: 118
Back to stocks